The patients with altered TSG pathway status, including TP53, CDKN2A, and SMAD4 mutations, had significantly lower CPS and immune/tumor cell rations, and higher smoking index than those without TSG alterations (Figures 4B, E–G and Supplementary Figure 5E). This evidence concerns the gene TP53 and neoplasm.